[Inhibitors of the key enzymes of androgen synthesis: potential agents as targets for prostate cancer].
Takeda
M
M
Department of Urology, Yokohama City University School of Medicine.
Hosaka
M
M
D015067:17-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors; D013739:Testosterone / Q000096:biosynthesis*
D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D018931:Antineoplastic Agents, Hormonal; D002227:Carbazoles; D004791:Enzyme Inhibitors; D007093:Imidazoles; C114168:YM 116; D013739:Testosterone; D015067:17-Hydroxysteroid Dehydrogenases; D013254:Steroid 17-alpha-Hydroxylase; C089740:abiraterone; C061121:liarozole; D007654:Ketoconazole